# DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

> **NCT06194695** · — · UNKNOWN · sponsor: **Ze-yang Ding, MD** · enrollment: 100 (estimated)

## Conditions studied

- Cholangiocarcinoma Non-resectable

## Interventions

- **PROCEDURE:** drug eluting beads-transcatheter arterial chemoembolization
- **DRUG:** envatinib plus anti-PD(L)1

## Key facts

- **NCT ID:** NCT06194695
- **Lead sponsor:** Ze-yang Ding, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06194695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06194695, "DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06194695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*